Jean‐Paul Fermand

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial

Jean‐Paul Fermand, Philippe Ravaud, Sylvie Chevret et al. · Blood · 1998 · 539 citations

Medicine, Hematology, Oncology +17

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

Arnaud Jaccard, Philippe Moreau, Véronique Leblond et al. · New England Journal of Medicine · 2007 · 518 citations

Medicine, Hematology, Oncology +14

High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe

Jean‐Paul Fermand, Sandrine Katsahian, Marine Diviné et al. · Journal of Clinical Oncology · 2005 · 401 citations · Full text

Medicine, Hematology, Oncology +17

A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

Jean‐Jacques Body, Philip R. Greipp, Robert E. Coleman et al. · Cancer · 2003 · 381 citations · Full text

Medicine, Oncology, Pharmacology +17